Read the article
To the Editor:
The American people are becoming aware that many pharmacies have recently begun offering generic medica- tions for only $4 for a one-month supply and $9 for a three-month supply. Although this is a very commendable and fiscally responsible act to benefit consumers, consumers could ultimately pay for it with their health if the FDA does not remain vigilant.
Most generic medications today are manufactured in Europe, India, or Israel and have regular and rigorous in- spections of their manufacturing process by the FDA. These manufacturers have a long history of providing safe, effec- tive, and reliable medications to consumers in the United States. The FDA requires generic drugs to be within the specified range of 80% to 120% effective as the brand-name medication they are replacing. The generic drug manufac- turers in Europe, India, and Israel have a proven track record of meeting those parameters set by the FDA and have always passed the rigorous inspections by the FDA for many years. The new player in the game is now China, and they are providing the generic medications to many phar- macies for their generic prescription plan and I hope they are subject to the same rigorous inspections by the FDA. Many, if not most, consumers are aware that in the past, China has had many problems with many of their manufac- turing industries, including but not limited to infant for- mula,1 dog food,2 lead paint on toys,3 and even generic drugs including heparin.4 I am not suggesting that China is not capable of manufacturing a high standard of products, but the aforementioned examples do raise the question about the safety of the generic drugs manufactured in China, and we need an assurance by our FDA in this regard. In my opinion, for the safety of American consumers, the Chinese manufacturers of generic drugs must comply with the FDA’s mandated inspections, and the FDA should assure us that this is being done. For consumers and health care providers, it is virtually impossible to know whether a medication is of poor quality or contaminated, until a trag- edy happens. Roger Williams, chief executive of the US Pharmacopeia, was quoted in 2007 saying, “We should be
concerned, because the US safety nets are frayed, and China has become a poster child for problems.”5 I hope that the Chinese government has put safeguards in to prevent recur- rence of an example in 2008 when heparin made from ingredients imported from China was linked to hundreds of serious adverse reactions, and included as many as 81 deaths in the United States.6
I have not been able to find whether the FDA has any contacts, jurisdiction, or other useful liaison with the Chi- nese generic drug manufacturers. We need the FDA to reassure us that they have some jurisdiction and/or moni- toring system in place, and that past problems with drug manufacturing have been adequately addressed in not only China but all of the other countries that supply us generic drugs.
Jon Durrani, DO
Swedish Covenant Hospital
References
Yadley J: China seeks to calm fears amid dairy scandal. New York Times on the Web, September 20, 2008. Available at: http://www. nytimes.com/2008/09/21/world/asia/21china.html?ref=melamine. Ac- cessed June 22, 2011.
Barboza D, Barrionuevo A: Filler in animal feed is open secret in China. New York Times on the Web, April 30, 2007. Available at: http:// www.nytimes.com/2007/04/30/business/worldbusiness/30food.html. Accessed June 22, 2011.
Story L: Lead paint prompts Mattel to recall 967,000 toys. New York Times on the Web, August 2, 2007. Available at: http://www. nytimes.com/2007/08/02/business/02toy.html. Accessed June 22, 2011.
Kaufman M: New data link heparin deaths to Chinese batches, FDA says. Washington Post on the Web, April 22, 2008. Available at: http://www.washingtonpost.com/wp-dyn/content/article/2008/04/21/ AR2008042101085.html. Accessed June 22, 2011.
Strauss E: “Fear factor accompanies drugs made in China.” nj.com, June 22, 2008. Available at: http://www.nj.com/business/index.ssf/ 2008/06/fear_factor_accompanies_generi.html. Accessed June 22, 2011.
Harris G: “U.S. identifies tainted heparin in 11 countries.” New York Times on the Web, April 22, 2008. Available at: http://www. nytimes.com/2008/04/22/health/policy/22fda.html. Accessed June 22, 2011.